Tempest Therapeutics, Inc. Restructuring and Related Cost, Cost Incurred to Date
Tempest Therapeutics, Inc. (TPST) had Restructuring and Related Cost, Cost Incurred to Date of $12.90 million as of 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2018-11-09
- 2018-09-30: Restructuring and Related Cost, Cost Incurred to Date $12.90M.
- 2018-06-30: Restructuring and Related Cost, Cost Incurred to Date $12.80M.
- 2018-03-31: Restructuring and Related Cost, Cost Incurred to Date $9.90M.
- 2017-12-31: Restructuring and Related Cost, Cost Incurred to Date $9.40M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2018-09-30 | $12.90M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $12.80M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $9.90M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $9.40M 10-K · filed 2018-03-15 |
| 2017-09-30 | $9.20M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $8.90M 10-Q · filed 2017-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |